Algia Pharma Receives FDA Support for Non-Opioid Pain Treatment AlgiaPak to Enter Phase 2 Trials
Key Insights
Algia Pharma (search) has received FDA support to advance AlgiaPak (search), a multimodal pain formulation designed to treat mild-to-moderate acute pain (search) as effectively as opioids without addiction risk.
The FDA recommended the 505(b)(2) regulatory pathway and expanded the indication from perioperative pain (search) to all mild-to-moderate acute pain (search), significantly broadening clinical potential.
IND-enabling studies are currently underway with results anticipated in the second quarter of 2026, following FDA recommendations to reduce study duration from seven to three days.
Algia Pharma (search) has received support from the U.S. Food and Drug Administration (FDA) to advance its novel non-opioid pain treatment AlgiaPak (search) toward a Phase 2 clinical trial upon completion of Investigational New Drug (IND)-enabling studies. The multimodal pain formulation is designed to treat all mild-to-moderate acute pain (search) as effectively as opioids without exposing patients to the risk of opioid addiction (search).
The company has initiated IND-enabling studies with results anticipated in the second quarter of 2026. AlgiaPak (search) combines multiple well-established, clinically proven medicines that act on non-opioid pain receptors (search) to stop pain transmission along the pain pathway into a single prescribing and dosing format.
FDA Expands Treatment Indication
The FDA provided positive feedback that significantly expanded AlgiaPak (search)'s potential clinical application. The agency broadened the initial indication from perioperative pain (search) to all mild-to-moderate acute pain (search), dramatically expanding both clinical and commercial potential.
"We are especially pleased the FDA broadened our initial indication beyond perioperative pain (search) to all mild-to-moderate acute pain (search), dramatically expanding clinical and commercial potential," said Joseph Loskove, M.D., co-founder and chief operating officer of Algia.
Streamlined Regulatory Pathway
The FDA recommended the 505(b)(2) regulatory pathway for AlgiaPak (search), which provides a lower-risk development route. The agency also recommended reducing the study duration from seven to three days. Algia intends to file for expedited review.
"We are encouraged by the FDA's detailed and positive feedback supporting a low-risk, accelerated development path," Loskove noted.
David Steinberg, Pharm.D., J.D., co-founder and chief executive officer of Algia, emphasized the treatment's potential impact: "Initiating these IND-enabling studies for AlgiaPak (search) is a major step forward in developing a safer, equally effective alternative to opioids to treat all mild-to-moderate acute pain (search)."
Clinical Foundation and Real-World Application
AlgiaPak (search) is intended to standardize hospital-grade multimodal pain control for outpatient use. According to Hannah Thompson, M.D., co-founder and chief medical officer of Algia, "Multimodal pain control is already widely implemented in hospitals, creating a strong base of clinical familiarity that supports uptake in the outpatient market. Every component of AlgiaPak is already safe and proven effective."
The formulation is engineered for real-world usability, providing simpler dosing and adherence with a single prescription rather than multiple scripts and confusing intervals.
Addressing Critical Unmet Medical Need
The development of AlgiaPak (search) addresses a significant public health crisis. More than 500,000 people die from drug overdoses globally each year, including more than 100,000 in the United States. Research shows that up to 10 percent of patients exposed to opioids under clinical care become addicted.
Despite the availability of effective alternatives, U.S. clinicians wrote nearly 142 million opioid pain prescriptions in 2020 alone. Multimodal non-opioid pain strategies have been clinically validated to achieve equivalent pain control for mild-to-moderate pain, but hospital-grade multimodal regimens have not been standardized for outpatient use, limiting access and adoption when patients leave the hospital setting.
Intellectual Property and Commercial Strategy
Algia has secured three issued U.S. patents, with additional filings underway in the U.S. and Europe. The company is developing a pricing strategy designed to be competitive with opioid prescriptions.
The company was founded by two anesthesiologists, Hannah Thompson, M.D., and Joseph Loskove, M.D., and pharmacist David Steinberg, Pharm.D., J.D., who together have decades of front-line experience in pain management.